Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

New Delhi (ANI): The Delhi Drugs Control Department conducted a special enforcement drive at a wholesale drug market in Delhi to ensure the availability of safe, effective and quality medicines to the public, particularly insulin preparations that require strict cold chain maintenance.

During the inspection, a total of six wholesale drug firms were inspected, out of which four firms were found violating provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. A large quantity of insulin preparations, including Tresiba FlexTouch 100U/ml Pen, Glaritus 100U/ml Cartridges, Humalog Mix50 KwikPen 100U/ml, Apidra SoloStar 100U/ml and Toujeo SoloStar 300U/ml, were found stocked with defaced inscriptions on labels that are meant for Government or institutional supply.

The concerned firms failed to produce valid purchase records for the said stock. Additionally, two firms were found storing insulin preparations at normal room temperature, in violation of prescribed storage conditions that mandate strict cold chain maintenance.

In total, 2,104 units of insulin preparations worth ₹20,06,024 were seized during the enforcement drive.

Speaking on the action, Delhi Health Minister Pankaj Kumar Singh said, “Ensuring the availability of safe and effective medicines for citizens is our foremost priority. Under the leadership of Hon’ble Chief Minister Smt. Rekha Gupta, the Delhi Government, is committed to maintaining strict regulatory oversight on drug storage and distribution. Any violation involving life-saving medicines like insulin will invite strict action under the law.”

Following the inspection, two firms have been booked for violations under the relevant provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. Additionally, drug samples have been collected and sent for testing and analysis to verify their quality and compliance with prescribed standards.

The Delhi Drugs Control Department reiterated its commitment to safeguarding public health and ensuring strict compliance with statutory provisions related to the storage and distribution of life-saving medicines. (ANI)

SOURCE : ANI

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre